CSAC Bulletin Article

Vaccine Approved as California Grapples with the Delta Variant 

August 26, 2021

Earlier this week, “Comirnaty,” Pfizer-BioNTech’s COVID-19 vaccine received full authorization by the Food and Drug Administration (FDA).

The Pfizer-BioNTech two-dose regimen has been distributed under an “emergency use authorization” for the past eight months. Following an in-depth review of trial data and millions of doses delivered, Comirnaty was approved, while the Moderna two-dose regimen and the single-dose Johnson&Johnson/Janssen product remain under emergency use authorization.

Doses of Comirnaty are authorized for those aged 16 and up. For those between 12 and 15, all three vaccines are still only approved for emergency use. Trials of all three vaccines in children younger than 12 are also in progress.

Authorization of Comirnaty is expected to persuade some vaccine-hesitant Californians to get vaccinated. As of August 23, according to the CDC, 79.4 percent of eligible Californians have received at least one dose of a vaccine.
 

How Exactly Do You Pronounce Comirnaty?

Courtesy of USA Today News (August 23, 2021), Click here for a direct link to the article.

The Pfizer-BioNTech vaccine is pronounced “co-MER-na-tee” according to Scott Piergrossi, president of creative for the Brand Institute, which crafted the name. 

It’s a little easier to say than BNT162b2, the research name of the vaccine while it was first being studied, but not much.

Why Comirnaty? According to the companies, it “represents a combination of the terms COVID-19, mRNA, community, and immunity.”

Navigation Term Highlight

Latest CSAC Bulletin

Navigation Term Highlight

Where We are Located

Navigation Term Highlight

County Of The Week:
Monterey